[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561902":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":20,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":20,"enrollmentInfo":38,"targetDuration":20,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":20,"overallStatus":47,"whyStopped":20,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":20},{"fullName":5,"class":6},"University of Maryland St. Joseph Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group - SCS","EXPERIMENTAL","Patients who are eligible will receive a trial implant for a 3-7 day trial period. If there is at least 50% pain relief in the trial period, the patients will receive the permanent SCS implant and will be followed for 1 year post permanent implant.",[13],"Device: Spinal Cord Stimulation Implant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Spinal Cord Stimulation Implant","Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Aja Janyavula, MD, MPH","CONTACT","4104275459","UMSJMCtrials@umm.edu",{"type":28,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100561902","phase-4-spinal-cord-stimulation-for-chemotherapy-induced-peripheral-neuropathy-100561902",false,"NCT06596200","Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy","Pilot Study for the Use of Spinal Cord Stimulation to Alleviate Pain from Chemotherapy Induced Peripheral Neuropathy Due to Taxane or Platinum Based Agents","Inclusion Criteria:\n\n* CIPN as diagnosed by Oncology and\u002For neurology\n* Receipt of a platinum-based or taxane chemotherapy prior to development of CIPN\n* Pain severity greater than 4 out of 10 on a numeric rating scale of pain\n* Pain chronicity greater than 6 months after the cessation of chemotherapy\n* Failure of medical therapy, which must have included duloxetine\n* Age 18 or greater\n\nExclusion Criteria:\n\n* Platelet count less than 100k\u002Fmm3\n* Spinal anatomy precluding placement of the SCS leads between T6 and T11\n* Active infection\n* Estimated Lifespan less than 1 year\n* Receipt of vincristine, thalidomide, bortezomib, or eribulin within the prior 12 months","ALL","18 Years",{"count":39,"type":40},10,"ESTIMATED","INTERVENTIONAL",[43],"PHASE4","Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord will be a safe and effective treatment for CIPN, reducing pain in the lower extremities by at least 50%.",[46],"Chemotherapy-induced Peripheral Neuropathy","NOT_YET_RECRUITING","2024-09-12",{"date":50,"type":51},"2024-09-19","ACTUAL",{"date":53,"type":40},"2024-09-15",{"date":55,"type":40},"2026-11-15",{"name":5,"class":6}]